NewAmsterdam Pharma Warrant
NAMSW
10 hedge funds and large institutions have $10.4M invested in NewAmsterdam Pharma Warrant in 2025 Q2 according to their latest regulatory filings, with funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.
27.13% more ownership
Funds ownership: 1.21% → 28.34% (+27%)
0% more funds holding
Funds holding: 10 → 10 (0)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
15% less capital invested
Capital invested by funds: $12.3M → $10.4M (-$1.89M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAA
Affinity Asset Advisors
New York
|
+$25.3K |
| 2 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$16.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$56.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$11.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FLSM
1
Frazier Life Sciences Management
Palo Alto,
California
| $4M | – | – | – |
|
|
RCM
2
RA Capital Management
Boston,
Massachusetts
| $2.67M | – | – | – |
|
|
AAA
3
Affinity Asset Advisors
New York
| $1.96M | +$25.3K | +3,043 | +1% |
|
|
BCLSI
4
Bain Capital Life Sciences Investors
Boston,
Massachusetts
| $800K | – | – | – |
|
|
DM
5
Deerfield Management
New York
| $742K | – | – | – |
|
|
LCM
6
Laurion Capital Management
New York
| $133K | – | – | – |
|
|
VI
7
Vestcor Inc
Fredericton,
New Brunswick, Canada
| $77K | – | – | – |
|
|
8
CIBC Private Wealth Group
Atlanta,
Georgia
| $24.2K | +$16.6K | +2,000 | +200% |
|
|
WAM
9
Wolverine Asset Management
Chicago,
Illinois
| $16.7K | -$56.5K | -6,793 | -76% |
|
|
10
UBS Group
Zurich,
Switzerland
| $7.94K | -$11.6K | -1,388 | -58% |
|
NAMSW Hedge Fund Activity: Q2 2025 in Review
10 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in NewAmsterdam Pharma Warrant (NAMSW) for Q2 2025, worth a combined $10.4M — down 15% from $12.3M a quarter earlier.
Fund positioning in NAMSW was balanced in Q2 2025: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 2 trimmed.
The largest buyer was Affinity Asset Advisors, adding an estimated $25.3K. The largest seller was Wolverine Asset Management, cutting an estimated $56.5K.
- 10 institutional investors held NewAmsterdam Pharma Warrant (NAMSW) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $10.4M of NewAmsterdam Pharma Warrant stock for Q2 2025, down 15% quarter-over-quarter.
- 0 funds opened new NewAmsterdam Pharma Warrant positions in Q2 2025 and 0 closed out.
- The largest NewAmsterdam Pharma Warrant buyer in Q2 2025 was Affinity Asset Advisors, an estimated $25.3K added.
- The largest NewAmsterdam Pharma Warrant seller in Q2 2025 was Wolverine Asset Management, an estimated $56.5K sold.
Based on aggregated 13F filings for Q2 2025.